Galantamine and memantine produce different degrees of neuroprotection in rat hippocampal slices subjected to oxygen-glucose deprivation

Neuroscience Letters

Volumn 365, Issue 2, 2004, Pages 132-136

  Sobrado, Mónica ^a   Roda, José M ^c   López, Manuela G ^a,b   Egea, Javier ^a   García, Antonio G ^a,b  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

acetylcholinesterase; AChE; allosteric potentiator ligand; APL; i.p.; intraperitoneal; lactate dehydrogenase; LDH; mean optical density; mOD; OGD; oxygen and glucose deprivation; Oxygen glucose deprivation; Transition Receptor Potential Cation Channel; TRPM

Indexed keywords

BICARBONATE; CHOLINESTERASE INHIBITOR; DIZOCILPINE; GALANTAMINE; GLUCOSE; LACTATE DEHYDROGENASE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NICOTINIC RECEPTOR; OXYGEN;

ANIMAL TISSUE; ANOXIA; ARTICLE; BRAIN SLICE; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME RELEASE; HIPPOCAMPUS; MALE; MONITORING; NERVE INJURY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; REOXYGENATION; TIME;

ANIMALS; CELL HYPOXIA; GALANTAMINE; GLUCOSE; HIPPOCAMPUS; L-LACTATE DEHYDROGENASE; MALE; MEMANTINE; NEUROPROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 3042732149     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2004.04.067     Document Type: Article

References (24)

1. Aarts M., Iihara K., Wei W.L., Xiong Z.G., Arundine M., Cerwinski W., MacDonald J.F., Tymianski M. A key role for TRPM7 channels in anoxic neuronal death. Cell. 115:2003;863-877
2. E. Alés, E. Arias, M.G. Lopez, Apamin-like effects of galantamine in chromaffin cells, in: Proceedings of the 12th International Symposium on Chromaffin Cell Biology, La Palma, Canary Islands, Spain, 21-25 September 2003.
3. Arias E., Alés E., Gabilán N.H., Cano-Abad M.F., Villarroya M., García A.G., López M.G. Galantamine prevents apoptosis induced by β-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors. Neuropharmacology. 46:2004;103-114
4. Capsoni S., Giannotta S., Cattaneo A. Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc. Natl. Acad. Sci. U.S.A. 99:2002;12432-12437
5. De Alba J., Cárdenas A., Moro M.A., Leza J., Lorenzo C.P., Lizasoain I. Use of brain slices in the study of pathogenic role of inducible nitric oxide synthase in cerebral ischemia-reperfusion. Gen. Pharmacol. 32:1999;577-581
6. Findlay D.J., Connelly P.J. Memantine (Ebixa) in the later stages of dementia. Hosp. Med. 64:2003;654-657
7. Francis P.T., Sims N.R., Procter A.W., Bowen D.M. Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease: investigative and therapeutic perspectives. J. Neurochem. 60:1993;1589-1604
8. Gorgulu A., Kins T., Cobanoglu S., Unal F., Izgi N.I., Yanik B., Kucuk M. Reduction of edema and infarction by Memantine and MK-801 after focal cerebral ischaemia and reperfusion in rat. Acta Neurochir. (Wien). 142:2000;1287-1292
9. Koh J.Y., Choi D.W. Quantitative determination of glutamate mediated cortical neuronal injury in cell culture by lactate dehydrogenase efflux assay. J. Neurosci. Methods. 20:1987;83-90
10. Koh Y., Cotman C.W. Programmed cell death: its possible contribution to neurotoxicity mediated by calcium channel antagonists. Brain Res. 587:1992;233-240
11. Kurz A.F., Erkinjuntti T., Small G.W., Lilienfeld S., Damaraju C.R. Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease. Eur. J. Neurol. 10:2003;633-640
12. Maelicke A., Schrattenholz A., Samochocki M., Radina M., Albuquerque E.X. Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease. Behav. Brain Res. 113:2000;199-206
13. Moro M.A., De Alba J., Cárdenas A., De Cristobal J., Leza J.C., Lizasoain I., Díaz-Guerra M.J., Bosca L., Lorenzo P. Mechanisms of the neuroprotective effect of aspirin after oxygen and glucose deprivation in rat forebrain. Neuropharmacology. 39:2000;1309-1318
14. Ni J.W., Matsumoto K., Li H.B., Murakami Y., Watanabe H. Neuronal damage and decrease of central acetylcholine level following permanent occlusion of bilateral common carotid arteries in rat. Brain Res. 673:1995;290-296
15. Parsons C.G., Danysz W., Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology. 38:1999;735-767
16. Paschen W. Dependence of vital cell function on endoplasmic reticulum calcium levels: implications for the mechanisms underlying neuronal cell injury in different pathological states. Cell Calcium. 29:2001;1-11
17. Raskind M.A., Peskind E.R., Wessel T., Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology. 54:2000;2261-2268
18. Reisberg B., Doody R., Stoffler A., Schmitt F., Ferris S., Mobius H.J. Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N. Engl. J. Med. 348:2003;1333-1341
19. Rytter A., Cronberg T., Asztely F., Nemali S., Wieloch T. Mouse hippocampal organotypic tissue cultures exposed to in vitro ischemia show selective and delayed CA1 damage that is aggravated by glucose. J. Cereb. Blood Flow Metab. 23:2003;23-33
20. Seif-el-Nasr M., Peruche B., Rossberg C., Mennel H.D., Krieglstein J. Neuroprotective effect of memantine demonstrated in vivo and in vitro. Eur. J. Pharmacol. 185:1990;19-24
21. Siesjo B.K., Zhao Q., Pahlmark K., Siesjo P., Katsura K., Folbergrova J. Glutamate, calcium, and free radicals as mediators of ischemic brain damage. Ann. Thorac. Surg. 59:1995;1316-1320
22. Tariot P.N., Solomon P.R., Morris J.C., Kershaw P., Lilienfeld S., Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The galantamine USA-10 Study Group. Neurology. 54:2000;2269-2276
23. Thomsen T., Kaden B., Fischer J.P., Bickel U., Barz H., Gusztony G., Cervos-Navarro J., Kewitz H. Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galanthamine, physostigmine and tacrine. Eur. J. Clin. Chem. Clin. Biochem. 29:1991;487-492
24. Traykova M., Traykov T., Hadjimitova V., Krikorian K., Bojadgieva N. Antioxidant properties of galantamine hydrobromide. Z. Naturforsch. 58:2003;361-365